Actively Recruiting
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Led by The First Affiliated Hospital of Xiamen University · Updated on 2026-05-15
100
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to assess how well 68Ga-NK224 positron emission tomography/computed tomography (PET/CT) can measure PD-L1 expression in primary and metastatic tumors in people with cancer. It compares PET/CT imaging results with tissue analysis through histopathology to better understand tumor characteristics. The study focuses on adults diagnosed with malignant tumors and evaluates imaging technology for its diagnostic value. Each participant receives a single intravenous injection of the imaging agent 68Ga-NK224, followed by PET/CT scans to capture images of tumors. Tumor uptake is measured using maximum and mean standardized uptake values (SUVmax and SUVmean). The PD-L1 expression in the tumors is then confirmed by examining tissue samples. This evaluation helps compare the imaging results with actual tissue findings. Participants undergo the PET/CT imaging and tissue analysis, with data collected to assess the agreement between imaging and histopathological results within 30 days. Researchers also evaluate variability in PD-L1 expression within and between tumors. Participants may be followed for up to 30 days to monitor outcomes. The study involves adults aged 18 to 90 years and includes patients with both newly diagnosed and previously treated cancers.
CONDITIONS
Brief Title
68Ga-NK224 PET Imaging of PD-L1 Expression in Cancers
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients aged 18 years or older
- Patients with newly diagnosed or previously treated malignant tumors confirmed by MRI, CT, tumor markers, or pathology
- Patients scheduled for 68Ga-NK224 PET/CT scans
- Patients able to provide informed consent and assent according to ethics guidelines
You will not qualify if you...
- Patients with non-malignant lesions
- Pregnant patients
- Patients or legal representatives unwilling or unable to provide written informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 30 days
Participants receive a single intravenous injection of 68Ga-NK224 and undergo PET/CT imaging to assess PD-L1 expression in tumors. Histopathological analysis of lesions confirms PD-L1 expression.
1 imaging visit and 1 biopsy visit
Trial Site Locations
Total: 1 location
1
The First Affiliated Hospital of Xiamen University
Xiamen, Fujian, China, 361000
Actively Recruiting
Research Team
L
Liang Zhao
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here